| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
69,020,000 |
| Market
Cap: |
106.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6003 - $3.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
94,704 |
7,518,862 |
| Total Buy Value |
$0 |
$0 |
$64,854 |
$66,954,067 |
| Total People Bought |
0 |
0 |
4 |
5 |
| Total Buy Transactions |
0 |
0 |
10 |
94 |
| Total Shares Sold |
0 |
0 |
0 |
85,082 |
| Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Svennilson Peter |
Director |
– • • |
2020-02-28 |
4 |
B |
$17.91 |
$676,998 |
I/I |
37,800 |
16,541,176 |
2.25 |
7% |
|
| Column Group Iii Gp, Lp |
General Partner |
– – • |
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
D/D |
33,896 |
336,469 |
2.45 |
12% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
D/D |
33,896 |
336,469 |
2.45 |
12% |
|
| Goeddel David V |
Director |
– • • |
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
I/I |
33,896 |
16,693,376 |
2.25 |
12% |
|
| Svennilson Peter |
Director |
– • • |
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
I/I |
33,896 |
16,503,376 |
2.25 |
12% |
|
| Column Group Iii Gp, Lp |
General Partner |
– – • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
D/D |
3,751 |
302,573 |
2.45 |
6% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
D/D |
3,751 |
302,573 |
2.45 |
6% |
|
| Goeddel David V |
Director |
– • • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
I/I |
3,751 |
16,659,480 |
2.25 |
6% |
|
| Svennilson Peter |
Director |
– • • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
I/I |
3,751 |
16,469,480 |
2.25 |
6% |
|
| Goeddel David V |
Director |
– • • |
2020-02-06 |
4 |
B |
$15.96 |
$716,604 |
I/I |
44,900 |
16,655,729 |
2.25 |
43% |
|
| Svennilson Peter |
Director |
– • • |
2020-02-06 |
4 |
B |
$15.96 |
$716,604 |
I/I |
44,900 |
16,465,729 |
2.25 |
43% |
|
| Column Group Iii Gp, Lp |
General Partner |
– – • |
2020-02-06 |
4 |
B |
$15.96 |
$716,604 |
D/D |
44,900 |
298,822 |
2.45 |
43% |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2020-02-06 |
4 |
B |
$15.96 |
$716,604 |
D/D |
44,900 |
298,822 |
2.45 |
43% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-09 |
4 |
S |
$17.95 |
$334,608 |
D/D |
(18,641) |
1,068,443 |
|
-21% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-09 |
4 |
OE |
$1.44 |
$26,843 |
D/D |
18,641 |
1,087,084 |
|
- |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-08 |
4 |
OE |
$0.52 |
$60,399 |
D/D |
87,784 |
1,068,443 |
|
- |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-08 |
4 |
S |
$17.98 |
$288,288 |
D/D |
(16,034) |
996,693 |
|
-21% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-07 |
4 |
S |
$18.20 |
$292,877 |
D/D |
(16,090) |
996,693 |
|
-17% |
|
| Chen Jin-Long |
Chief Scientific Officer |
• • – |
2020-01-07 |
4 |
OE |
$1.44 |
$23,170 |
D/D |
16,090 |
1,012,783 |
|
- |
|
| Column Group Iii Gp, Lp |
General Partner |
– – • |
2019-11-11 |
4 |
B |
$12.00 |
$180 |
D/D |
15 |
253,922 |
2.37 |
- |
|
| Column Group Ii Gp, Lp |
General Partner |
– – • |
2019-11-11 |
4 |
B |
$12.00 |
$180 |
D/D |
15 |
253,922 |
2.37 |
- |
|
| Svennilson Peter |
Director |
– • • |
2019-11-11 |
4 |
B |
$12.00 |
$180 |
I/I |
15 |
16,420,829 |
2.17 |
- |
|
| Goeddel David V |
Director |
– • • |
2019-11-11 |
4 |
B |
$12.00 |
$180 |
I/I |
15 |
16,610,829 |
2.17 |
- |
|
| Svennilson Peter |
Director |
– • • |
2019-11-04 |
4 |
B |
$11.99 |
$100,824 |
I/I |
8,409 |
16,420,814 |
2.25 |
- |
|
| Column Group Iii Gp, Lp |
General Partner |
– – • |
2019-11-04 |
4 |
B |
$11.99 |
$100,824 |
D/D |
8,409 |
253,907 |
2.45 |
- |
|
499 Records found
|
|
Page 13 of 20 |
|
|
